Ono Akira, Freed Eric O
Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA.
J Virol. 2004 Feb;78(3):1552-63. doi: 10.1128/jvi.78.3.1552-1563.2004.
The human immunodeficiency virus type 1 (HIV-1) assembly-and-release pathway begins with the targeting of the Gag precursor to the site of virus assembly. The molecular mechanism by which Gag is targeted to the appropriate subcellular location remains poorly understood. Based on the analysis of mutant Gag proteins, we and others have previously demonstrated that a highly basic patch in the matrix (MA) domain of Gag is a major determinant of Gag transport to the plasma membrane. In this study, we determined that in HeLa and T cells, the MA mutant Gag proteins that are defective in plasma membrane targeting form virus particles in a CD63-positive compartment, defined as the late endosome or multivesicular body (MVB). Interestingly, we find that in primary human macrophages, both wild-type (WT) and MA mutant Gag proteins are targeted specifically to the MVB. Despite the fact that particle assembly in macrophages occurs at an intracellular site rather than at the plasma membrane, we observe that WT Gag expressed in this cell type is released as extracellular virions with high efficiency. These results demonstrate that Gag targeting to and assembly in the MVB are physiologically important steps in HIV-1 virus particle production in macrophages and that particle release in this cell type may follow an exosomal pathway. To determine whether Gag targeting to the MVB is the result of an interaction between the late domain in p6(Gag) and the MVB sorting machinery (e.g., TSG101), we examined the targeting and assembly of Gag mutants lacking p6. Significantly, the MVB localization of Gag was still observed in the absence of p6, suggesting that an interaction between Gag and TSG101 is not required for Gag targeting to the MVB. These data are consistent with a model for Gag targeting that postulates two different cellular binding partners for Gag, one on the plasma membrane and the other in the MVB.
1型人类免疫缺陷病毒(HIV-1)的组装与释放途径始于Gag前体靶向病毒组装位点。Gag靶向至合适亚细胞位置的分子机制仍知之甚少。基于对突变型Gag蛋白的分析,我们和其他研究人员此前已证明,Gag基质(MA)结构域中的一个高度碱性区域是Gag转运至质膜的主要决定因素。在本研究中,我们确定,在HeLa细胞和T细胞中,质膜靶向有缺陷的MA突变型Gag蛋白在一个CD63阳性区室中形成病毒颗粒,该区域被定义为晚期内体或多泡体(MVB)。有趣的是,我们发现,在原代人巨噬细胞中,野生型(WT)和MA突变型Gag蛋白均特异性靶向至MVB。尽管巨噬细胞中的颗粒组装发生在细胞内位点而非质膜,但我们观察到,在这种细胞类型中表达的WT Gag能高效释放为细胞外病毒粒子。这些结果表明,Gag靶向至MVB并在其中组装是HIV-1在巨噬细胞中产生病毒颗粒的生理重要步骤,且这种细胞类型中的颗粒释放可能遵循外泌体途径。为了确定Gag靶向至MVB是否是p6(Gag)中的晚期结构域与MVB分选机制(如TSG101)之间相互作用的结果,我们检测了缺乏p6的Gag突变体的靶向和组装情况。值得注意的是,在没有p6的情况下,仍观察到Gag定位于MVB,这表明Gag靶向至MVB不需要Gag与TSG101之间的相互作用。这些数据与一种Gag靶向模型一致,该模型假定Gag有两个不同的细胞结合伴侣,一个在质膜上,另一个在MVB中。